Submission Ide: 88c19114-7d71-4703-b679-22f6c2ee5804
79% SIMILARITY SCORE 4 CITATION ITEMS 66 GRAMMAR ISSUES 0 FEEDBACK COMMENT
Internet Source 79%
Institution 0%
Muhammad Aftkhar
Parkinsonism- Pharmaceutical Treatment Plan.docx
Summary
1140 Words
1
Running Header: PARKINSON'S DISEASE
2
PARKINSON'S DISEASE
Parkinson’s disease
Parkinson's disease is a neuro de-generative disease that occurs and depletes the neurons
present in substansia nigra. These neurons are involved in the transmission of nerve impulses
Web Content: https://mynursingexperts.com/checking-and-assignment-corection/…
Spelling mistake: neuro euro
Spelling mista...: de-generative degenerative
PARKINSON'S DISEASE
MUHAMMAD AFTKHAR
NUR 635 (GCU)
Mar 4th, 2020
https://www.researchgate.net/profile/Charles_Davie/publication/5454757_A_review_of_Parkinson's_disease/links/5866522a08ae8fce490ee2e6/A-review-of-Parkinsons-disease.pdf
https://www.researchgate.net/profile/Charles_Davie/publication/5454757_A_review_of_Parkinson's_disease/links/5866522a08ae8fce490ee2e6/A-review-of-Parkinsons-disease.pdf
https://www.sciencedirect.com/science/article/abs/pii/S1474442218302394
https://www.sciencedirect.com/science/article/abs/pii/S1043661818321078
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4140171/
from corpus collosum to the susbtansia nigra part of the mid brain. These are the character
playing neurons in managing voluntary motor movements in the body. It mostly occurs in elderly
patients describe by involuntary movements and multi-dimensional brain functioning. The part
of this disease may occur due to the effective and excessive use of medications indulging in bi
polar or Alzheimer's disease (Davie, 2008). The decline of dopamine in par compacta
deteriorates the normal functioning of the brain in controlling motor activities.
Prescription medication
The prescribed medications used for Parkinson’s disease includes the use of Levodopa
directly with replenishes the pool for dopamine neurotransmitter. This drug can’t be given in a
single dose rather without carbidopa (LODOSYN) the levodopa will break down into dopamine
and then to epinephrine in the body’s periphery. This will create severe symptomatic side effects
like an increase in heart rate and sympathetic system dominancy. Dopa-decarboxylase enzyme
breaks down the levodopa in the periphery so along with levodopa carbidopa is given. This
inhibits the dopa-decarboxylase enzyme and allows levodopa to travel into the blood brain
barrier easily.
For the calculations of drug regimen there must be precautionary measures for kidney
and liver sensitive enzyme dependent patients. LFT and RFT’s for sensitive patients are done to
ensure the correct for dose adjustments not lying in range affecting kidneys and liver function.
Below are some of the medications for Parkinson’s d.
Parkinson's disease is a progressive neurological disorder that causes tremors, rigidity, and slowed movement. It results from the loss of dopamine-producing neurons in the substantia nigra. Primary Parkinson's has no known cause while secondary Parkinsonism can be caused by drugs, toxins, infections, or other neurological conditions. Symptoms are treated pharmacologically with levodopa and other dopamine agonists to replace lost dopamine, though no treatment can stop the progression of the disease. Advanced cases may be treated with surgery such as deep brain stimulation.
Parkinson's disease is a progressive neurological disorder that results from the loss of dopamine-producing neurons in the brain. The main symptoms include tremors, rigidity, slow movement, and impaired balance and coordination. There is no cure for Parkinson's, but treatments can help manage the motor symptoms by replacing dopamine or mimicking its effects in the brain. Diet and nutrition also play an important role, as the disease can affect swallowing, digestion and weight. Maintaining a healthy diet with small, frequent meals and modifying protein intake is recommended. Exercise is also encouraged to help with symptoms and overall well-being. While Parkinson's is not fatal, complications from the disease are a leading cause of death.
Parkinson disease is a progressive neurodegenerative disorder characterized by motor and non-motor symptoms. It is caused by the loss of dopamine-producing neurons in the brain and affects millions worldwide. The symptoms were first described in 1817 and include tremors, stiffness, slow movement, and impaired balance and coordination. While its progression cannot be stopped, symptoms can be effectively treated with dopamine replacement therapy such as levodopa. Advanced disease brings new challenges of managing motor fluctuations between periods of good control and poor control.
Parkinson's disease is a progressive brain disorder that occurs when certain nerve cells in the substantia nigra die or become impaired, reducing dopamine levels and causing movement problems. Key signs include tremors, slow movement, rigidity, and balance issues. While the cause is largely unknown, genetics and environmental toxins like pesticides may play a role. Current treatment options include medications and deep brain stimulation surgery, but there is no cure. Research is exploring potential therapies like stem cell transplants and compounds in green tea.
Parkinson's disease is a brain disorder that occurs when certain nerve cells in the substantia nigra die or become impaired, reducing dopamine production. The key signs are tremor, slowness of movement, rigidity, and difficulty with balance. While symptoms usually develop after age 65, 15% of cases are younger patients. Current treatments include medications and deep brain stimulation surgery, but there is no known cure. Support groups and maintaining a healthy lifestyle can help patients manage their condition. Further research through clinical trials continues in hopes of finding a cure.
PARKINSONS DISEASE MEDICAL TREATMENT AND PHYSIOTHERAPY MANAGEMENT Srinitha Busam
This presentation contains brief description about parkinsons disease , its medical management and physiotherapy management ( aims of rehabilitation and exercise training for parkinsons disease patient)
Emerging trends in the diagnosis and treatment of Parkinson's disease were presented. For diagnosis, machine learning algorithms like XGBoost are being used to detect early symptoms, and graphene-based biosensors are in development. Promising new treatment approaches include stem cell therapy, gene therapy, immunotherapies targeting alpha-synuclein, regenerative therapies, and drugs targeting autophagy, iron, or calcium pathways that are undergoing clinical trials. Future directions may involve reducing alpha-synuclein, neuroprotective drugs, gene therapies, and other targeted mechanisms to better manage symptoms and progression of Parkinson's disease.
Parkinson's disease is a progressive neurological disorder that causes tremors, rigidity, and slowed movement. It results from the loss of dopamine-producing neurons in the substantia nigra. Primary Parkinson's has no known cause while secondary Parkinsonism can be caused by drugs, toxins, infections, or other neurological conditions. Symptoms are treated pharmacologically with levodopa and other dopamine agonists to replace lost dopamine, though no treatment can stop the progression of the disease. Advanced cases may be treated with surgery such as deep brain stimulation.
Parkinson's disease is a progressive neurological disorder that results from the loss of dopamine-producing neurons in the brain. The main symptoms include tremors, rigidity, slow movement, and impaired balance and coordination. There is no cure for Parkinson's, but treatments can help manage the motor symptoms by replacing dopamine or mimicking its effects in the brain. Diet and nutrition also play an important role, as the disease can affect swallowing, digestion and weight. Maintaining a healthy diet with small, frequent meals and modifying protein intake is recommended. Exercise is also encouraged to help with symptoms and overall well-being. While Parkinson's is not fatal, complications from the disease are a leading cause of death.
Parkinson disease is a progressive neurodegenerative disorder characterized by motor and non-motor symptoms. It is caused by the loss of dopamine-producing neurons in the brain and affects millions worldwide. The symptoms were first described in 1817 and include tremors, stiffness, slow movement, and impaired balance and coordination. While its progression cannot be stopped, symptoms can be effectively treated with dopamine replacement therapy such as levodopa. Advanced disease brings new challenges of managing motor fluctuations between periods of good control and poor control.
Parkinson's disease is a progressive brain disorder that occurs when certain nerve cells in the substantia nigra die or become impaired, reducing dopamine levels and causing movement problems. Key signs include tremors, slow movement, rigidity, and balance issues. While the cause is largely unknown, genetics and environmental toxins like pesticides may play a role. Current treatment options include medications and deep brain stimulation surgery, but there is no cure. Research is exploring potential therapies like stem cell transplants and compounds in green tea.
Parkinson's disease is a brain disorder that occurs when certain nerve cells in the substantia nigra die or become impaired, reducing dopamine production. The key signs are tremor, slowness of movement, rigidity, and difficulty with balance. While symptoms usually develop after age 65, 15% of cases are younger patients. Current treatments include medications and deep brain stimulation surgery, but there is no known cure. Support groups and maintaining a healthy lifestyle can help patients manage their condition. Further research through clinical trials continues in hopes of finding a cure.
PARKINSONS DISEASE MEDICAL TREATMENT AND PHYSIOTHERAPY MANAGEMENT Srinitha Busam
This presentation contains brief description about parkinsons disease , its medical management and physiotherapy management ( aims of rehabilitation and exercise training for parkinsons disease patient)
Emerging trends in the diagnosis and treatment of Parkinson's disease were presented. For diagnosis, machine learning algorithms like XGBoost are being used to detect early symptoms, and graphene-based biosensors are in development. Promising new treatment approaches include stem cell therapy, gene therapy, immunotherapies targeting alpha-synuclein, regenerative therapies, and drugs targeting autophagy, iron, or calcium pathways that are undergoing clinical trials. Future directions may involve reducing alpha-synuclein, neuroprotective drugs, gene therapies, and other targeted mechanisms to better manage symptoms and progression of Parkinson's disease.
20180202 3 j. lombard genomind milan relazione part 2 to pub.pptxRoberto Scarafia
https://www.linkedin.com/pulse/simposio-toma-implementazione-della-farmacogenetica-nel-scarafia/
https://www.linkedin.com/pulse/malattie-psichiatriche-e-neurologiche-arriva-toma-il-test-scarafia/
2 febbraio 2018, Sala Congressi Laboratorio TOMA
Relatori: Dr. J. Lombard, Dr.ssa F.R. Grati, Dr.ssa S. De Toffol
BREVE PREMESSA
La farmacogenetica studia l’influenza dei fattori genetici sull’attività di un farmaco, la sua assimilazione e il suo metabolismo allo scopo di massimizzarne l’efficacia terapeutica e minimizzare gli effetti avversi. I fattori genetici possono giustificare fino al 95% della variabilità interpersonale nella risposta e nelle reazioni avverse a determinati trattamenti farmacologici. Finora la diagnosi ed il trattamento farmacologico in psichiatria si sono basati principalmente sul un protocollo ‘trial and error’ tramite colloquio, osservazione clinica e analisi di laboratorio costituivano esclusivamente un complemento per valutare possibili effetti collaterali o i livelli plasmatici di alcuni farmaci. L’introduzione di test di farmacogenetica consente di fornire al clinico informazioni costitutive dell’individuo relativamente al metabolismo di molti farmaci e la potenziale risposta in determinati contesti clinici al fine di ridurre i tempi ottenimento del trattamento efficace personalizzato e arricchire con le più recenti informazioni genetiche la gestione terapeutica dei pazienti.
OBIETTIVI FORMATIVI
Introdurre i principi scientifici alla base del test genetico che si presenterà durante il corso, il significato, la funzione e la rilevanza clinica per la salute mentale di ciascun gene indagato dal test;
L’utilità clinica del test Genecept: presentare come vengono riportati i risultati del test e come meglio interpretarli;
Presentare alcuni casi clinici reali per discutere circa l’utilità di un trattamento farmacologico guidato dai risultati del test genetico rispetto all’approccio tradizionale ‘trial and error’
Advances in Management of Parkinson's DiseaseSultana Shaikh
Parkinson's disease [PD] is one of the most common neurodegenerative disorders. There have been significant recent advances in the understanding of the pathogenesis of the disease. There has also been a greater realization that the disorder may be associated with significant non-motor disturbances in addition to the more commonly recognized motor complications. There are many drugs like levodopa and carbidopa, ropinirole, pramipexole, rotigotine etc. and some MAO-B INHIBITOR like selegiline and rasagiline which are used in treatment of Parkinson’s disease. Some COMT INHIBITOR
and others drugs are also available and some herbs like turmeric, ginger, garlic etc. provides temporary relief from Parkinson’s disease. There are two vaccines which are under development for the treatment of Parkinson’s disease.
Nanoparticles show promise for treating Parkinson's disease. Albumin/PLGA nanoparticles conjugated with dopamine improved motor skills in mouse models more than free L-DOPA. Liposomes coated with a peptide derived from rabies virus and carrying a dopamine derivative enhanced cellular uptake and brain penetration. Extracellular vesicles may also help by delivering protective agents, growth factors, dopamine, or silencing alpha-synuclein to reduce symptoms in mouse models. Overall, nanomedicine approaches aim to more effectively deliver drugs to the brain and slow progression of Parkinson's disease.
This document proposes a randomized controlled study to investigate the effects of bright light therapy on sleep and mood disorders in Parkinson's disease. 80 Parkinson's patients will be included and randomized to either real or placebo light therapy groups. Primary outcomes will be mood measures, and sleep parameters, motor symptoms, physiological markers, and biological rhythms will also be assessed if additional funding is obtained. The goal is to develop an effective non-pharmacological therapy to improve sleep, mood, and quality of life for Parkinson's patients.
This document discusses using induced pluripotent stem cells (iPSCs) derived from a patient's own skin cells to generate dopamine-producing neurons for treating Parkinson's disease. Parkinson's involves the death of dopamine neurons in the brain. Previous research using embryonic stem cells in rodents led to tumor formation. The proposed methodology would involve taking skin cells from rodents, generating iPSCs, differentiating them into dopamine neurons, and surgically implanting them into the rodents' brains. This approach could reduce immunorejection risks and provide a new treatment for Parkinson's by replacing lost dopamine neurons. Future studies would assess the safety and effectiveness of this iPSC-based therapy.
Personalized medicine uses a person's genetic information to guide disease prevention, diagnosis, and treatment decisions. Pharmacogenomics studies how a person's genetic variations affect their response to drugs, allowing doctors to select medications and doses tailored to an individual. For example, genetic testing can identify patients likely to experience dangerous reactions to certain drugs like carbamazepine and abacavir, allowing doctors to prescribe alternative medications. New technologies like bioelectronic medicines, 3D printing, and telepharmacy further enable personalized approaches through localized drug delivery, customized dosing, and remote care.
This document provides an overview of Parkinson's disease including its symptoms, pathophysiology, risk factors, genetic mutations, and treatment options. It discusses how Parkinson's is a progressive neurodegenerative disorder resulting from the loss of dopaminergic neurons in the substantia nigra. The motor symptoms are attributed to striatal dopamine depletion and include tremors, bradykinesia, rigidity, and others. Non-motor symptoms can also occur. Current treatment focuses on replacing dopamine or stimulating dopamine receptors through medications like levodopa, dopamine agonists, MAO-B inhibitors, and others.
This document discusses factors that influence individual variability in drug response, including physiological, genetic, disease state, environmental, and psychological factors. It notes that alterations in drug absorption, distribution, metabolism, elimination, or target receptors can all impact drug effects. Genetic polymorphisms can also play a role in how individuals respond to certain drugs through variations in drug metabolizing enzymes or receptors. These differences must be considered when determining appropriate drug dosing for each individual patient.
Dextroprorpoxyphene is an opioid analgesic used to treat mild pain, cough, and muscle cramps. It acts as an agonist at mu-opioid receptors in the brain and gastrointestinal tract, reducing the perception of pain. However, it can cause dependency among recreational users and has a narrow therapeutic index. A clinical study of 60 patients compared the effects of dextroprorpoxyphene to traditional non-opioid drugs for various conditions like pain, depression, and bronchitis. The study aimed to evaluate dextroprorpoxyphene's adverse effects and judicious use.
Dextropropoxyphene is an opioid analgesic used to treat mild to moderate pain. It acts on opioid receptors in the brain and spinal cord to reduce pain perception and increase tolerance. While it can be effective for its approved uses, it also carries risks of dependency and cardiac side effects when taken in high doses or combined with other central nervous system depressants like alcohol. A clinical study was conducted of 60 patients taking dextropropoxyphene to treat pain, depression, or other conditions. Most patients reported significant relief of symptoms with no side effects after 3 days of treatment. However, dextropropoxyphene must be prescribed judiciously due to its risks and potential for abuse.
ABSTRACT- Neurodegenerative diseases (NDDs) are traditionally defined as disorders with selective loss of neurons and distinct involvement of functional systems defining clinical presentation. Alzheimer’s Disease, being one of the most detrimental Neurodegenerative diseases, an irreversible, progressive brain disorder with changes in nerve cells resulting in their death and furthermore leading to the loss of intellectual and cognitive abilities. Despite the commercial availability of few drugs, Alzheimer’s disease is the sixth leading causes of death globally and the major public health concern, owing to a constraining coercion for action against it. For the same, many drug targets were identified of which one among the most potential one’s is the Microtubule- associated Tau protein that contributes to the pathological lesions of Alzheimer’s disease, the Neurofibrillary Tangles or Paired Helical Filaments. Believing that preventing the formation of these pathological lesions, the Neurofibrillary Tangles, is much more a prominent strategy, in the present study, two approaches one approach plying compounds belonging to the class of Cannabinoids and the other approach employing a set of small molecules were used, with the help of Bioinformatics tools, such as Discovery Studio in designing the therapeutic molecules that can obliquely and potentially combat against these Neurofibrillary Tangles or NFTs and actuate to reduce their content in neurons, which might result in an improved communication and thereby enhancing the condition of the diseased person.
Key-words- Alzheimer’s disease, Cannabinoids, Cognitive abilities, Discovery Studio, Neurofibrillary Tangles, Tau protein
Efficacy of ITI 007 Related with Mood Regulation and Mental Disorderijtsrd
Schizophrenia imposes a heavy burden on both the individual and society. A wide range of symptoms, including as psychosis, hallucinations, delusions, and associated positive feelings, as well as difficulties in social functioning, cognitive problems, and, frequently, debilitating mood disorders like chronic depression, are used to describe the disease. Often, lifelong medication is necessary for the diseases management. A novel antipsychotic drug called lumateperone ITI 007, CAPLYTATM was discovered and created by Intra Cellular Therapies, Inc. ITCI and was authorized for the treatment of schizophrenia in adults in December 2019. Serotonin, dopamine, and glutamate neurotransmission, three important neurotransmitters linked to schizophrenia, are simultaneously modulated by lumateperone. The US Food and Drug Administration has authorized its use. Patients with treatment resistant schizophrenia and those who are at risk of developing metabolic dysfunction should take into account using lumateperone abnormalities of movement. Lumateperone should not be used, however, in the following situations a women who are pregnant or nursing b children, adolescents, and elderly patients with dementia related psychosis c patients who are at risk for cerebrovascular diseases d patients who use alcohol or other sedative drugs and e patients who use inducers and moderate or strong inhibitors of the cytochrome P450 3A4 CYP3A4 isozyme. Future research will lay the groundwork for identifying the proof for thorough analyses of the function of lumateperone in the treatment of those with schizophrenia and other illnesses. Ms. Bhusare Kalpana Marutirao | Mr. Salvi Ajay Sanjay "Efficacy of ITI-007 Related with Mood Regulation and Mental Disorder" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-7 | Issue-4, August 2023, URL: https://www.ijtsrd.com/papers/ijtsrd59645.pdf Paper Url:https://www.ijtsrd.com/pharmacy/other/59645/efficacy-of-iti007-related-with-mood-regulation-and-mental-disorder/ms-bhusare-kalpana-marutirao
Autophagy Pathways as Pharmacological Target in Parkinson's DiseaseAhmedAlgaliSedahmed
The document summarizes the relationship between autophagy pathways and Parkinson's disease. It finds that:
1) Failure of autophagy results in the accumulation of toxic protein aggregates in neurons, which can lead to neurodegeneration as seen in Parkinson's disease. Studies in mice and human cells support the role of impaired autophagy in Parkinson's pathology.
2) Several genes associated with Parkinson's disease are involved in autophagy regulation. Manipulating autophagy pathways has shown therapeutic potential in preclinical models of Parkinson's, though selectivity and context-dependence are challenges.
3) Personalized approaches may be needed, as autophagy enh
The future of treatments for PD psych research symposium poster 1_20162Morgan Stafford
This document provides information on Parkinson's disease (PD) and current research. It discusses:
- LRRK2 gene mutations as a common genetic cause of PD and how they disrupt protein recycling and cause cell death.
- Current treatments for PD like drugs that supplement dopamine or inhibit enzymes that break it down, but these only treat symptoms and have side effects.
- Promising research on closed-loop deep brain stimulation and cell transplant therapies that could modify disease progression.
- Ongoing clinical studies of these future treatments and the hope they provide for improving PD treatment.
The document provides information on Parkinson's disease (PD), including its causes, symptoms, diagnosis and management. Some key points:
- PD is caused by degeneration of dopamine-producing neurons in the substantia nigra, leading to motor symptoms like tremor, rigidity and bradykinesia.
- It also causes non-motor symptoms like depression, anxiety and sleep problems. Symptoms typically begin on one side of the body.
- Diagnosis is based on clinical criteria and can be supported by imaging and other tests. Management includes medications, exercise, dietary changes and other therapies to improve motor and non-motor symptoms.
This research article examines the potential disease-modifying effect of adiponectin (APN) in models of alpha-synucleinopathies such as Parkinson's disease and dementia with Lewy bodies. The study finds that APN is localized within Lewy bodies in human brain tissue from patients with these conditions. In cell and mouse models expressing alpha-synuclein, APN treatment suppressed alpha-synuclein aggregation, phosphorylation, and release through an AdipoR1-AMPK pathway. Intranasal APN treatment in transgenic mice improved histopathology and motor function when initiated early. APN may exert these effects by modifying metabolic pathways to have a therapeutic potential for alpha-synu
This research article examines the potential disease-modifying effect of adiponectin (APN) in models of alpha-synucleinopathies such as Parkinson's disease and dementia with Lewy bodies. The study finds that APN is localized in Lewy bodies in autopsy brain samples of patients with these conditions. In neuronal cell models expressing alpha-synuclein, APN treatment reduces aggregation and phosphorylation of alpha-synuclein through an AdipoR1-AMP kinase pathway. Intranasal APN treatment in transgenic mouse models also improves histopathology and movement disorders when initiated early. The study suggests APN may suppress neurodegeneration through metabolic pathway modification and have therapeutic potential for alpha-
Parkinson's disease is a neurodegenerative disorder caused by the loss of dopamine-producing neurons in the substantia nigra. The main symptoms are motor symptoms like tremors and rigidity, as well as non-motor symptoms like depression and sleep disorders. Diagnosis is based on the presence of cardinal motor features and there are no definitive medical tests. Current treatments aim to replace dopamine or stimulate dopamine receptors through drugs. Emerging treatments include gene therapy, stem cell therapy, deep brain stimulation surgery, and alternative therapies like acupuncture. Researchers are developing new drug formulations and therapies to better treat Parkinson's symptoms like bradykinesia and tremors that remain problematic.
Submit a 2-page Reading Response that uses either The Latino Th.docxdavid4611
Submit a 2-page Reading Response that uses either "The Latino Threat Narrative" OR
Deported
to interpret the example of Carlos from
A Better Life.
As before, this is a mini-essay that offers a reading of the work and supports that reading. Begin with your
Sentence Summary
instead of your Literary Analysis. Make sure to include the following:
1. Paragraph 1--A one-sentence summary of the work, following the Sentence Summary template below:
Sentence Summary Template
: In [title of work], [author's first and last name], [author's job title], argues that because [cause of trend], [main idea or problematic trend], leading to [effects of problematic trend], citing [author's main source of evidence], such as [specific example from the author's evidence].
Sample Sentence Summary
: In
Kids for Cash
, Robert May, Academy Award-winning filmmaker, reveals that because schools have adopted zero-tolerance policies in fear of school shootings, schools, police, and courts are criminalizing youth for minor offenses, leading to the mass incarceration of youth, their separation from their families, disenfranchisement from educational opportunities, mental and emotional health problems such as PTSD, anxiety, and depression, and even overdose and suicide, citing data on national incarceration rates of youth, such as 2.2 million youth are incarcerated every year, 95 percent of which are for non-violent offenses and 66 percent of whom will not graduate.
2. Paragraph 2--A
body paragraph
that interprets the example of Luis offered in A Better Life through the lens of "Cultural Misframing" or "Multiple Manhoods" by going through the following moves:
Quoting or paraphrasing scenes or examples from the film and the essay (specifying or detailing)
Interpreting the scenes, examples, or passages you quote (interpreting)
Analyzing the takeaway significance of the examples (generalizing or analyzing)
Sample Reading Response:
Victoria Valdovinos
Dr. Stevenson
English 1B
20 March, 2019
Reading Response #5 ("Alienable")
In "Alienable" about a young woman in her 20s who has recently ended a two-year relationship and is trying to console with her friend, Jay, until she realizes people are shielding themselves from the sun like they do not know it is not raining, Yuko Sakata suggests that in relationships it, at times, can be difficult to connect with the other person since people often have differing desires and can change in ways that become incompatible with each other.
In any type of relationship, people will often times have trouble connecting with the other person for several reason, and one is having not only what you yearn for in the present, but what you will long for in the future. In a romantic relationship this can certainly be the make it or break it point. If the partners recognize that they have common goals and similar desires then the relationship could be nascent However, when the partners realize they have different aspiration.
Submit a 2-page document in which you highlight the important co.docxdavid4611
Submit a 2-page document in which you highlight the important contributions of the individual you selected. Your document should
Outline the individual’s path to working in the social work field.
Describe the most important contribution(s) of the individual to the field.
Explain how the study of this individual would inform your practice as a social worker.
Adhere to APA conventions.
This paper will be on Jane Addams. Due 04/30/2020 by 10:30 PM.
.
More Related Content
Similar to Submission Ide 88c19114-7d71-4703-b679-22f6c2ee580479 SI.docx
20180202 3 j. lombard genomind milan relazione part 2 to pub.pptxRoberto Scarafia
https://www.linkedin.com/pulse/simposio-toma-implementazione-della-farmacogenetica-nel-scarafia/
https://www.linkedin.com/pulse/malattie-psichiatriche-e-neurologiche-arriva-toma-il-test-scarafia/
2 febbraio 2018, Sala Congressi Laboratorio TOMA
Relatori: Dr. J. Lombard, Dr.ssa F.R. Grati, Dr.ssa S. De Toffol
BREVE PREMESSA
La farmacogenetica studia l’influenza dei fattori genetici sull’attività di un farmaco, la sua assimilazione e il suo metabolismo allo scopo di massimizzarne l’efficacia terapeutica e minimizzare gli effetti avversi. I fattori genetici possono giustificare fino al 95% della variabilità interpersonale nella risposta e nelle reazioni avverse a determinati trattamenti farmacologici. Finora la diagnosi ed il trattamento farmacologico in psichiatria si sono basati principalmente sul un protocollo ‘trial and error’ tramite colloquio, osservazione clinica e analisi di laboratorio costituivano esclusivamente un complemento per valutare possibili effetti collaterali o i livelli plasmatici di alcuni farmaci. L’introduzione di test di farmacogenetica consente di fornire al clinico informazioni costitutive dell’individuo relativamente al metabolismo di molti farmaci e la potenziale risposta in determinati contesti clinici al fine di ridurre i tempi ottenimento del trattamento efficace personalizzato e arricchire con le più recenti informazioni genetiche la gestione terapeutica dei pazienti.
OBIETTIVI FORMATIVI
Introdurre i principi scientifici alla base del test genetico che si presenterà durante il corso, il significato, la funzione e la rilevanza clinica per la salute mentale di ciascun gene indagato dal test;
L’utilità clinica del test Genecept: presentare come vengono riportati i risultati del test e come meglio interpretarli;
Presentare alcuni casi clinici reali per discutere circa l’utilità di un trattamento farmacologico guidato dai risultati del test genetico rispetto all’approccio tradizionale ‘trial and error’
Advances in Management of Parkinson's DiseaseSultana Shaikh
Parkinson's disease [PD] is one of the most common neurodegenerative disorders. There have been significant recent advances in the understanding of the pathogenesis of the disease. There has also been a greater realization that the disorder may be associated with significant non-motor disturbances in addition to the more commonly recognized motor complications. There are many drugs like levodopa and carbidopa, ropinirole, pramipexole, rotigotine etc. and some MAO-B INHIBITOR like selegiline and rasagiline which are used in treatment of Parkinson’s disease. Some COMT INHIBITOR
and others drugs are also available and some herbs like turmeric, ginger, garlic etc. provides temporary relief from Parkinson’s disease. There are two vaccines which are under development for the treatment of Parkinson’s disease.
Nanoparticles show promise for treating Parkinson's disease. Albumin/PLGA nanoparticles conjugated with dopamine improved motor skills in mouse models more than free L-DOPA. Liposomes coated with a peptide derived from rabies virus and carrying a dopamine derivative enhanced cellular uptake and brain penetration. Extracellular vesicles may also help by delivering protective agents, growth factors, dopamine, or silencing alpha-synuclein to reduce symptoms in mouse models. Overall, nanomedicine approaches aim to more effectively deliver drugs to the brain and slow progression of Parkinson's disease.
This document proposes a randomized controlled study to investigate the effects of bright light therapy on sleep and mood disorders in Parkinson's disease. 80 Parkinson's patients will be included and randomized to either real or placebo light therapy groups. Primary outcomes will be mood measures, and sleep parameters, motor symptoms, physiological markers, and biological rhythms will also be assessed if additional funding is obtained. The goal is to develop an effective non-pharmacological therapy to improve sleep, mood, and quality of life for Parkinson's patients.
This document discusses using induced pluripotent stem cells (iPSCs) derived from a patient's own skin cells to generate dopamine-producing neurons for treating Parkinson's disease. Parkinson's involves the death of dopamine neurons in the brain. Previous research using embryonic stem cells in rodents led to tumor formation. The proposed methodology would involve taking skin cells from rodents, generating iPSCs, differentiating them into dopamine neurons, and surgically implanting them into the rodents' brains. This approach could reduce immunorejection risks and provide a new treatment for Parkinson's by replacing lost dopamine neurons. Future studies would assess the safety and effectiveness of this iPSC-based therapy.
Personalized medicine uses a person's genetic information to guide disease prevention, diagnosis, and treatment decisions. Pharmacogenomics studies how a person's genetic variations affect their response to drugs, allowing doctors to select medications and doses tailored to an individual. For example, genetic testing can identify patients likely to experience dangerous reactions to certain drugs like carbamazepine and abacavir, allowing doctors to prescribe alternative medications. New technologies like bioelectronic medicines, 3D printing, and telepharmacy further enable personalized approaches through localized drug delivery, customized dosing, and remote care.
This document provides an overview of Parkinson's disease including its symptoms, pathophysiology, risk factors, genetic mutations, and treatment options. It discusses how Parkinson's is a progressive neurodegenerative disorder resulting from the loss of dopaminergic neurons in the substantia nigra. The motor symptoms are attributed to striatal dopamine depletion and include tremors, bradykinesia, rigidity, and others. Non-motor symptoms can also occur. Current treatment focuses on replacing dopamine or stimulating dopamine receptors through medications like levodopa, dopamine agonists, MAO-B inhibitors, and others.
This document discusses factors that influence individual variability in drug response, including physiological, genetic, disease state, environmental, and psychological factors. It notes that alterations in drug absorption, distribution, metabolism, elimination, or target receptors can all impact drug effects. Genetic polymorphisms can also play a role in how individuals respond to certain drugs through variations in drug metabolizing enzymes or receptors. These differences must be considered when determining appropriate drug dosing for each individual patient.
Dextroprorpoxyphene is an opioid analgesic used to treat mild pain, cough, and muscle cramps. It acts as an agonist at mu-opioid receptors in the brain and gastrointestinal tract, reducing the perception of pain. However, it can cause dependency among recreational users and has a narrow therapeutic index. A clinical study of 60 patients compared the effects of dextroprorpoxyphene to traditional non-opioid drugs for various conditions like pain, depression, and bronchitis. The study aimed to evaluate dextroprorpoxyphene's adverse effects and judicious use.
Dextropropoxyphene is an opioid analgesic used to treat mild to moderate pain. It acts on opioid receptors in the brain and spinal cord to reduce pain perception and increase tolerance. While it can be effective for its approved uses, it also carries risks of dependency and cardiac side effects when taken in high doses or combined with other central nervous system depressants like alcohol. A clinical study was conducted of 60 patients taking dextropropoxyphene to treat pain, depression, or other conditions. Most patients reported significant relief of symptoms with no side effects after 3 days of treatment. However, dextropropoxyphene must be prescribed judiciously due to its risks and potential for abuse.
ABSTRACT- Neurodegenerative diseases (NDDs) are traditionally defined as disorders with selective loss of neurons and distinct involvement of functional systems defining clinical presentation. Alzheimer’s Disease, being one of the most detrimental Neurodegenerative diseases, an irreversible, progressive brain disorder with changes in nerve cells resulting in their death and furthermore leading to the loss of intellectual and cognitive abilities. Despite the commercial availability of few drugs, Alzheimer’s disease is the sixth leading causes of death globally and the major public health concern, owing to a constraining coercion for action against it. For the same, many drug targets were identified of which one among the most potential one’s is the Microtubule- associated Tau protein that contributes to the pathological lesions of Alzheimer’s disease, the Neurofibrillary Tangles or Paired Helical Filaments. Believing that preventing the formation of these pathological lesions, the Neurofibrillary Tangles, is much more a prominent strategy, in the present study, two approaches one approach plying compounds belonging to the class of Cannabinoids and the other approach employing a set of small molecules were used, with the help of Bioinformatics tools, such as Discovery Studio in designing the therapeutic molecules that can obliquely and potentially combat against these Neurofibrillary Tangles or NFTs and actuate to reduce their content in neurons, which might result in an improved communication and thereby enhancing the condition of the diseased person.
Key-words- Alzheimer’s disease, Cannabinoids, Cognitive abilities, Discovery Studio, Neurofibrillary Tangles, Tau protein
Efficacy of ITI 007 Related with Mood Regulation and Mental Disorderijtsrd
Schizophrenia imposes a heavy burden on both the individual and society. A wide range of symptoms, including as psychosis, hallucinations, delusions, and associated positive feelings, as well as difficulties in social functioning, cognitive problems, and, frequently, debilitating mood disorders like chronic depression, are used to describe the disease. Often, lifelong medication is necessary for the diseases management. A novel antipsychotic drug called lumateperone ITI 007, CAPLYTATM was discovered and created by Intra Cellular Therapies, Inc. ITCI and was authorized for the treatment of schizophrenia in adults in December 2019. Serotonin, dopamine, and glutamate neurotransmission, three important neurotransmitters linked to schizophrenia, are simultaneously modulated by lumateperone. The US Food and Drug Administration has authorized its use. Patients with treatment resistant schizophrenia and those who are at risk of developing metabolic dysfunction should take into account using lumateperone abnormalities of movement. Lumateperone should not be used, however, in the following situations a women who are pregnant or nursing b children, adolescents, and elderly patients with dementia related psychosis c patients who are at risk for cerebrovascular diseases d patients who use alcohol or other sedative drugs and e patients who use inducers and moderate or strong inhibitors of the cytochrome P450 3A4 CYP3A4 isozyme. Future research will lay the groundwork for identifying the proof for thorough analyses of the function of lumateperone in the treatment of those with schizophrenia and other illnesses. Ms. Bhusare Kalpana Marutirao | Mr. Salvi Ajay Sanjay "Efficacy of ITI-007 Related with Mood Regulation and Mental Disorder" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-7 | Issue-4, August 2023, URL: https://www.ijtsrd.com/papers/ijtsrd59645.pdf Paper Url:https://www.ijtsrd.com/pharmacy/other/59645/efficacy-of-iti007-related-with-mood-regulation-and-mental-disorder/ms-bhusare-kalpana-marutirao
Autophagy Pathways as Pharmacological Target in Parkinson's DiseaseAhmedAlgaliSedahmed
The document summarizes the relationship between autophagy pathways and Parkinson's disease. It finds that:
1) Failure of autophagy results in the accumulation of toxic protein aggregates in neurons, which can lead to neurodegeneration as seen in Parkinson's disease. Studies in mice and human cells support the role of impaired autophagy in Parkinson's pathology.
2) Several genes associated with Parkinson's disease are involved in autophagy regulation. Manipulating autophagy pathways has shown therapeutic potential in preclinical models of Parkinson's, though selectivity and context-dependence are challenges.
3) Personalized approaches may be needed, as autophagy enh
The future of treatments for PD psych research symposium poster 1_20162Morgan Stafford
This document provides information on Parkinson's disease (PD) and current research. It discusses:
- LRRK2 gene mutations as a common genetic cause of PD and how they disrupt protein recycling and cause cell death.
- Current treatments for PD like drugs that supplement dopamine or inhibit enzymes that break it down, but these only treat symptoms and have side effects.
- Promising research on closed-loop deep brain stimulation and cell transplant therapies that could modify disease progression.
- Ongoing clinical studies of these future treatments and the hope they provide for improving PD treatment.
The document provides information on Parkinson's disease (PD), including its causes, symptoms, diagnosis and management. Some key points:
- PD is caused by degeneration of dopamine-producing neurons in the substantia nigra, leading to motor symptoms like tremor, rigidity and bradykinesia.
- It also causes non-motor symptoms like depression, anxiety and sleep problems. Symptoms typically begin on one side of the body.
- Diagnosis is based on clinical criteria and can be supported by imaging and other tests. Management includes medications, exercise, dietary changes and other therapies to improve motor and non-motor symptoms.
This research article examines the potential disease-modifying effect of adiponectin (APN) in models of alpha-synucleinopathies such as Parkinson's disease and dementia with Lewy bodies. The study finds that APN is localized within Lewy bodies in human brain tissue from patients with these conditions. In cell and mouse models expressing alpha-synuclein, APN treatment suppressed alpha-synuclein aggregation, phosphorylation, and release through an AdipoR1-AMPK pathway. Intranasal APN treatment in transgenic mice improved histopathology and motor function when initiated early. APN may exert these effects by modifying metabolic pathways to have a therapeutic potential for alpha-synu
This research article examines the potential disease-modifying effect of adiponectin (APN) in models of alpha-synucleinopathies such as Parkinson's disease and dementia with Lewy bodies. The study finds that APN is localized in Lewy bodies in autopsy brain samples of patients with these conditions. In neuronal cell models expressing alpha-synuclein, APN treatment reduces aggregation and phosphorylation of alpha-synuclein through an AdipoR1-AMP kinase pathway. Intranasal APN treatment in transgenic mouse models also improves histopathology and movement disorders when initiated early. The study suggests APN may suppress neurodegeneration through metabolic pathway modification and have therapeutic potential for alpha-
Parkinson's disease is a neurodegenerative disorder caused by the loss of dopamine-producing neurons in the substantia nigra. The main symptoms are motor symptoms like tremors and rigidity, as well as non-motor symptoms like depression and sleep disorders. Diagnosis is based on the presence of cardinal motor features and there are no definitive medical tests. Current treatments aim to replace dopamine or stimulate dopamine receptors through drugs. Emerging treatments include gene therapy, stem cell therapy, deep brain stimulation surgery, and alternative therapies like acupuncture. Researchers are developing new drug formulations and therapies to better treat Parkinson's symptoms like bradykinesia and tremors that remain problematic.
Similar to Submission Ide 88c19114-7d71-4703-b679-22f6c2ee580479 SI.docx (20)
Submit a 2-page Reading Response that uses either The Latino Th.docxdavid4611
Submit a 2-page Reading Response that uses either "The Latino Threat Narrative" OR
Deported
to interpret the example of Carlos from
A Better Life.
As before, this is a mini-essay that offers a reading of the work and supports that reading. Begin with your
Sentence Summary
instead of your Literary Analysis. Make sure to include the following:
1. Paragraph 1--A one-sentence summary of the work, following the Sentence Summary template below:
Sentence Summary Template
: In [title of work], [author's first and last name], [author's job title], argues that because [cause of trend], [main idea or problematic trend], leading to [effects of problematic trend], citing [author's main source of evidence], such as [specific example from the author's evidence].
Sample Sentence Summary
: In
Kids for Cash
, Robert May, Academy Award-winning filmmaker, reveals that because schools have adopted zero-tolerance policies in fear of school shootings, schools, police, and courts are criminalizing youth for minor offenses, leading to the mass incarceration of youth, their separation from their families, disenfranchisement from educational opportunities, mental and emotional health problems such as PTSD, anxiety, and depression, and even overdose and suicide, citing data on national incarceration rates of youth, such as 2.2 million youth are incarcerated every year, 95 percent of which are for non-violent offenses and 66 percent of whom will not graduate.
2. Paragraph 2--A
body paragraph
that interprets the example of Luis offered in A Better Life through the lens of "Cultural Misframing" or "Multiple Manhoods" by going through the following moves:
Quoting or paraphrasing scenes or examples from the film and the essay (specifying or detailing)
Interpreting the scenes, examples, or passages you quote (interpreting)
Analyzing the takeaway significance of the examples (generalizing or analyzing)
Sample Reading Response:
Victoria Valdovinos
Dr. Stevenson
English 1B
20 March, 2019
Reading Response #5 ("Alienable")
In "Alienable" about a young woman in her 20s who has recently ended a two-year relationship and is trying to console with her friend, Jay, until she realizes people are shielding themselves from the sun like they do not know it is not raining, Yuko Sakata suggests that in relationships it, at times, can be difficult to connect with the other person since people often have differing desires and can change in ways that become incompatible with each other.
In any type of relationship, people will often times have trouble connecting with the other person for several reason, and one is having not only what you yearn for in the present, but what you will long for in the future. In a romantic relationship this can certainly be the make it or break it point. If the partners recognize that they have common goals and similar desires then the relationship could be nascent However, when the partners realize they have different aspiration.
Submit a 2-page document in which you highlight the important co.docxdavid4611
Submit a 2-page document in which you highlight the important contributions of the individual you selected. Your document should
Outline the individual’s path to working in the social work field.
Describe the most important contribution(s) of the individual to the field.
Explain how the study of this individual would inform your practice as a social worker.
Adhere to APA conventions.
This paper will be on Jane Addams. Due 04/30/2020 by 10:30 PM.
.
Submit a 2-page Reading Response for the river In essenc.docxdavid4611
Submit a 2-page Reading Response for "the river"
In essence, this is a mini-essay that offers a reading of the work and supports that reading. Make sure to include the following:
1. Paragraph 1--A
thesis
or one-sentence interpretation of the work, following the Literary Analysis template below:
In [title of work], about [POV-person] [description of POV-person] who [rising action] until [climax/point-of-no-return], [author or director] suggests that [main idea] since [reason A] and [reason B].
2. Paragraph 2--A
body paragraph
that supports your reading of the work by going through the following moves:
Quoting or paraphrasing scenes or examples from the work (specifying or detailing)
Interpreting the scenes or examples you quote (interpreting)
Analyzing the takeaway significance of the examples (generalizing or analyzing)
.
Submit a 2- to 3-page paper that addresses the followingO.docxdavid4611
Submit
a 2- to 3-page paper that addresses the following:
Overview: I
ncluding your reasons for selecting the theory for deeper investigation instead of other potential theories.
History:
Provide an overview of the major historical developments of this theory and explain their significance. Consider the following:
How did the theory emerge in the intellectual landscape?
What was the critical research that led to this theory’s acceptance in the professional and/or academic communities?
What additional research molded and shaped this theory over time? In other words, what new information emerged by using this theory in additional research or practice?
.
Submit a 2- to 4-page paper that includes the following.docxdavid4611
Submit
a 2- to 4-page paper that includes the following:
A description of the services in your local community that support individuals in later adulthood
An evaluation of the effectiveness of the services you identified
A description of service gaps you identified
An explanation of how to improve existing services
A description of services that should be added, and why
Below is more information you can find on the services Mississippi provide for later adulthood
https://www.mdhs.ms.gov/adults-seniors/services-for-seniors/
.
Submit a 2 to 3-page paper in which youBriefly describe an .docxdavid4611
Submit
a 2 to 3-page paper in which you:
Briefly describe an interaction you observed or in which you participated, where a person’s lack of cultural awareness influenced their communication with someone of a different culture. Make sure to include the cultures of the people and the cultural context.
Based on what you learned in this week’s resources, explain how you can tell the person lacked cultural awareness and analyze how this lack of cultural awareness affected his or her communication with the other people involved.
.
Subject Pollution Must follow all directions BI 301 Term Pape.docxdavid4611
Subject Pollution
Must follow all directions
BI 301 Term Paper Assignment—Core Assessment
Create a research paper in the specific CSE format and style that provides an overview of a specific environmental problem, endangered or threatened species, or environmentally-sensitive ecosystem approved by the instructor. The paper should be at least 10 pages in length (double spaced and 10-12 point font) excluding title page, table of contents, tables, figures, and literature cited A well-defined introduction, thesis statement, body (and sections within), and conclusion should be apparent. Information covered in the paper should include:
Assignment Issues:
Define the ecological problem and its causes.
Incorporate interrelatedness of other species in the same area.
Incorporate interrelatedness of abiotic resources in the same area
Describe anthropogenic influences on the problem.
Discuss several solutions and their associated drawbacks.
Describe how other cultures or nations are affected by, and view, this problem.
.
Submission date 11282019The requirement is to come up with .docxdavid4611
Submission date: 11/28/2019
The requirement is to come up with a detailed write up of everything required to build an e-commerce website / mobile application or windows application.
Project write up will need to include the below:
1) Project Title
2) Abstract
3) Current system / shortcomings / solution
4) Important Milestones
5) Software / Tools to be utilized
6) Budget / Finance
7) Detail project plan represented using a Gantt Chart
8) Database design E-R Diagram using preferably Crow's Foot Notation
9) Final documentation ( including all details of the project for final presentation)
Note: All templates will be provided upon acceptance
.
Submission - MarkUpSubmission MarkUp This is a machine generated.docxdavid4611
Submission - MarkUpSubmission MarkUp This is a machine generated report of your submission document containing error details as annotations. Details of all points deducted in the submitted document are listed on this sheet.Assignment DetailsSubmission ID4456338400Assignment NameExcel Chapter 2 Grader ProjectSubmission Date19 February, 2020Report Generated on28 February, 2020Points Obtained53.364/100 (53.364%)Worksheet: 'New Clients' (Points Deducted: 46.636)Points DeductedDetailsError Description39.636Cell level Incorrect Actions50 cell(s) commented inplace. Please check the sheet.2.000Incorrect Actions: Sheet (New Clients)2.000 point(s) deducted in instruction #12:
-In the Sheet 'New Clients' the 'fit to pages' was not applied.5.000Incorrect Actions: Header(s)/Footer(s)5.000 point(s) deducted in instruction #13:
-In the Sheet 'New Clients' the 'Center Footer Text Case' was not set as per instruction.
-In the Sheet 'New Clients' the 'Center Footer Content' was not set to '&[Date]'.
-In the Sheet 'New Clients' the 'Right Footer Text Case' was not set as per instruction.
-In the Sheet 'New Clients' the 'Right Footer Content' was not set to '&[File]'.
New ClientsHealth & Fitness GymDate Prepared:2/17/20
Project Error:: Project Error:
5 point(s) deducted in instruction #3:
- In the Cell 'B2' of Sheet 'New Clients', the 'Formula' was not set to 'TODAY()'.Client
Project Error:: Project Error:
0.385 point(s) deducted in instruction #11:
- In the Cell(s) 'A4', 'B4', 'C4', 'D4', 'E4', 'F4', 'G4', 'H4', 'I4', 'J4', 'A17', 'B17', 'C17' of Sheet 'New Clients', the 'Wrap Text' was not applied.Membership
Project Error:: Project Error:
0.385 point(s) deducted in instruction #11:
- In the Cell(s) 'A4', 'B4', 'C4', 'D4', 'E4', 'F4', 'G4', 'H4', 'I4', 'J4', 'A17', 'B17', 'C17' of Sheet 'New Clients', the 'Wrap Text' was not applied.Cost
Project Error:: Project Error:
0.385 point(s) deducted in instruction #11:
- In the Cell(s) 'A4', 'B4', 'C4', 'D4', 'E4', 'F4', 'G4', 'H4', 'I4', 'J4', 'A17', 'B17', 'C17' of Sheet 'New Clients', the 'Wrap Text' was not applied.Locker
Project Error:: Project Error:
0.384 point(s) deducted in instruction #11:
- In the Cell(s) 'A4', 'B4', 'C4', 'D4', 'E4', 'F4', 'G4', 'H4', 'I4', 'J4', 'A17', 'B17', 'C17' of Sheet 'New Clients', the 'Wrap Text' was not applied.Annual Total
Project Error:: Project Error:
0.385 point(s) deducted in instruction #11:
- In the Cell(s) 'A4', 'B4', 'C4', 'D4', 'E4', 'F4', 'G4', 'H4', 'I4', 'J4', 'A17', 'B17', 'C17' of Sheet 'New Clients', the 'Wrap Text' was not applied.Years
Project Error:: Project Error:
0.384 point(s) deducted in instruction #11:
- In the Cell(s) 'A4', 'B4', 'C4', 'D4', 'E4', 'F4', 'G4', 'H4', 'I4', 'J4', 'A17', 'B17', 'C17' of Sheet 'New Clients', the 'Wrap Text' was not applied.Total Due
Project Error:: Project Error:
0.385 point(s) deducted in instruction #11:
- In the Cell(s) 'A4', 'B4', 'C4', 'D4', 'E4', 'F4', 'G4', 'H4', 'I4', 'J4', 'A17.
Submission Use your selected business plan template to complete t.docxdavid4611
Submission:
Use your selected business plan template to complete the Business Plan.
Prepare to submit your Business Plan.
Design a Cover Page for the business plan that includes relevant information. The Cover Page is the first impression so make it look impressive.
Create an Executive Summary. In presenting the plan to your financing source this is the first thing they will read. You must make it engaging and compelling so they will want to look at the details contained within the plan. This is the single most important element of the plan to anyone looking at it for the first time.
Create a Table of Contents.
Organize the information from the prior assignments within the body of the plan so the information is presented Plan updated for any comments you have received or any additional research or ideas you wish to include.
APA format and Word .doc/.docx
.
subject:Theologytopic:reflection paper (helping the church yard .docxdavid4611
subject:Theology
topic:reflection paper (helping the church yard sale event, make sure kids don’t get hurt by running around, washing dishes.
format :12 point Times New Roman, one inch margins, double spaced, cover page, Spelling and grammar will be a part of the grade
(I did it with my friend Simon and Rico)
.
This document is a digital receipt from Turnitin acknowledging receipt of a submission. It provides key details about the submitted assignment such as the submission author, assignment title, file name, file size, page count, word count, character count, and submission date and ID. The first page of the submitted document is displayed on the receipt.
SUBJECT Security Architecture & DesignTo enhance the security.docxdavid4611
SUBJECT: Security Architecture & Design
To enhance the security of information systems, enterprises are developing and adopting information system management systems. However, if an information management system is exploited, applications and the data they contain will be compromised. Therefore, it is important to perform comprehensive threat modeling throughout the enterprise.
In your own words explain (a) what is threat modeling, and (b) why it is important for an enterprise to address threat modeling extensively. Please state your answer in a 2 page paper in APA format. Include citations and sources in APA style.
"No plagiarism"
Learning Materials and References (Prof posted in course syllabus)
Required Resources
Shostack, Adam.
Threat Modeling: Designing for Security
, Indianapolis, IN: Wiley, 2014
Recommended Resources
Please use the following author’s names, book/article titles, Web sites, and/or keywords to search for supplementary information to augment your learning in this subject.
Tony UcedaVelez and Marco M. Morana
Rick Centric Threat Modeling: Process for Attack Simulation and Threat Analysis
Grading Criteria Assignments Maximum Points
Meets or exceeds established assignment criteria 40
Demonstrates an understanding of lesson concepts 20
Clearly presents well-reasoned ideas and concepts 30
Uses proper mechanics, punctuation, sentence structure, spelling and APA structure 10
Total 100
.
Submission Requirements Format Microsoft Word (or compatible).docxdavid4611
Submission Requirements
? Format: Microsoft Word (or compatible)
? Font: Arial, size 12, double-space
? Citation Style: Follow your school�s preferred style guide
? Length: 2 page
? APA Format
? No resources before 2015
? Must complete all parts to answer the questions
*** will be reviewed for plagiarism prior to all grading
“Your Company” is expanding. The company wants additional network controls to protect their growing network.
Tasks
Consider the Windows servers and workstations in the domains of a typical IT infrastructure. Based on your understanding of network security controls, recommend at least four possible controls that will enhance the network’s security. Focus on ensuring that controls satisfy the defense in depth approach to security.
Summarize your network security controls in a summary report to management.
You must provide rationale for your choices by explaining how each control makes the environment more secure and what potential flaws the controls have as well.
Global
editionGlo
b
a
l
ed
it
io
n
this is a special edition of an established
title widely used by colleges and universities
throughout the world. Pearson published this
exclusive edition for the benefit of students
outside the United States and Canada. if you
purchased this book within the United States
or Canada you should be aware that it has
been imported without the approval of the
Publisher or author.
Pearson Global Edition
Global
edition
For these Global editions, the editorial team at Pearson has
collaborated with educators across the world to address a
wide range of subjects and requirements, equipping students
with the best possible learning tools. this Global edition
preserves the cutting-edge approach and pedagogy of the
original, but also features alterations, customization, and
adaptation from the north american version.
it
Strategy:
Issues and Practices
M
cK
een
Sm
ith
it Strategy
Issues and Practices
tHiRd edition
James D. McKeen • Heather A. Smith
t
H
iR
d
e
d
it
io
n
McKeen_1292080264_mech.indd 1 28/11/14 12:56 PM
IT STraTegy:
ISSueS and PracTIceS
A01_MCKE0260_03_GE_FM.indd 1 26/11/14 9:32 PM
A01_MCKE0260_03_GE_FM.indd 2 26/11/14 9:32 PM
IT STraTegy:
ISSueS and PracTIceS
T h i r d E d i t i o n
G l o b a l E d i t i o n
James D. McKeen
Queen’s University
Heather A. Smith
Queen’s University
Boston Columbus Indianapolis New York San Francisco Hoboken
Amsterdam Cape Town Dubai London Madrid Milan Munich Paris Montréal Toronto
Delhi Mexico City São Paulo Sydney Hong Kong Seoul Singapore Taipei Tokyo
A01_MCKE0260_03_GE_FM.indd 3 26/11/14 9:32 PM
Editor in Chief: Stephanie Wall
Head of Learning Asset Acquisition, Global Edition: Laura Dent
Acquisitions Editor: Nicole Sam
Program Manager Team Lead: Ashley Santora
Program Manager: Denise Vaughn
Editorial Assistant: Kaylee Rotella
Assistant Acquisitions Editor, Global Edition: Debapriya Mu.
Submission Requirements Answer all the questions included in th.docxdavid4611
Submission Requirements
:
Answer all the questions included in the lab. You can submit your answers in a Microsoft Word document, or write your answers on paper and then scan and submit the paper. Name the file as InitialName_LastName_Lab10.1_Date.
Evaluation Criteria:
·
Did you show the relevant steps in doing problems?
·
Did you write thorough explanations for the short-answer questions?
·
Did you submit your answers in an organized fashion that was legible and easy to follow?
·
Were the answers correct?
.
Subject Law – Case LawRequested Due Date 061914 500PM EDT.docxdavid4611
Subject:
Law – Case Law
Requested Due Date
: 06/19/14 5:00PM EDT
Scenario One
Joanna Spring always insisted that she did not ever want to be kept alive by machines, and even stated that when she was a young teenager. Her parents understood her feelings on the subject. Joanna married Bill Spring and one month later, was involved in an auto accident which left her in a persistent vegetative state. Joanna’s parents (Mr. and Mrs. John Winters) have sued to have Joanna taken off life support. Joanna’s husband refused to allow the hospital to do so. Joanna’s parents thing that it is only because he will not inherit Joanna’s huge estate unless he has been married to her for more than two years. The court sided with Bill Spring, and refused to order the removal of life support. The Winters now want to appeal the decision and let Joanna die in peace before bill becomes Joanna’s heir.
Scenario Two
Shirley Baker is a young woman suffering from breast cancer. She has been on chemotherapy for several months, and has experienced terrible side-effects. She did receive a prescription for the medicinal use of marijuana while living in California, but moved to Oklahoma to be closer to her family. She did take several ounces of marijuana with her when she moved, and was arrested while smoking marijuana on the front porch of her parent’s home, the evening she arrived in Oklahoma. She was convicted of illegal possession of the drug, and wants to appeal her conviction.
Scenario Three
Joe Valle and Fred Hamper have been partners for many years. When same sex unions became legal in California, they moved there just long enough to be “married,” and then returned to their home in New Mexico. Joe applied for health insurance for himself and his “spouse.” The insurance company refused to recognize the “marriage,’ and Joe and Fred sued. The trial court found in favor of Big Time Insurance Company, and Joe and Fred want to appeal.
Scenario Four
Flora Findley loves plants. She had become interested in hydroponics and hybridizing plants. She began growing plants under full-spectrum sunlight lamps in her home. She also has a teenaged son who expressed an interest in growing plants. She was pleased that she and her son could share an interest. One day, a police officer investigating a burglary next door, came to Flora’s home to ask if she had seen anything. He noticed all of the plants growing under the lamps, and quickly began inspecting them. He found a small plant that he thought was marijuana, and promptly arrested Flora. Flora was convicted for possession, but insisted that the search of her home was unwarranted. She wants to appeal the decision.
Scenario Five
Mr. Frank Incense was arrested for theft when he took $500,000 worth of tools from behind a neighbor’s shed which faced an alley. Frank insisted that he thought the tools were being thrown away. He was having financial difficulty and thought he could make some money by selling the tools. While being quest.
SubjectiveCC My stomach hurts, I have diarrhea and nothing .docxdavid4611
A 47-year-old man presented with 3 days of abdominal pain rated 5/10, diarrhea, and nausea after eating. His medical history included hypertension, diabetes, and a prior gastrointestinal bleed. On examination, he had an elevated temperature and tenderness in his left lower quadrant. Additional diagnostic testing was needed to evaluate for possible causes like gastroenteritis or diverticulitis.
Subject Sex Tourism Compare and contrast at least two countries.docxdavid4611
Subject: Sex Tourism
Compare and contrast at least two countries where sex tourism can be found (Thailand and Brazil). Is it legal or illegal? Who goes to these destinations (men? women?) What are some of the regional health issues? Crime? How does nation manage their sex industry?
11 slides
Relaible sources
.
Submission Date May 21st 2021Residency AssignmentRes.docxdavid4611
Submission Date : May 21st 2021
Residency Assignment
Research Paper
As we have discussed in class, Blockchain is a rapidly emerging technology that will disrupt global business.
Write a paper that explores in detail how blockchain will revolutionize a particular area of business. Do
NOT
choose cryptocurrency or supply chain for your business vertical.
Requirements:
Length
Minimum 10 pages / Maximum 20 pages
The title page and references pages do not count towards the page length requirements.
Double spaced
Times New Roman Font
APA style (
https://owl.english.purdue.edu/owl/resource/560/01/
)
At least 5 works cited
At least 2 of your references have to be scholarly peer-reviewed articles
Research paper will be checked for plagiarism so be sure to correctly cite your sources!
Research Presentation
Goal is to summarize your research paper
PowerPoint Presentation is required and must be submitted inside of iLearn
Must present for at least 10 minutes but no more than 15 minutes
All group members
need to participate in the presentation
.
Andreas Schleicher presents PISA 2022 Volume III - Creative Thinking - 18 Jun...EduSkills OECD
Andreas Schleicher, Director of Education and Skills at the OECD presents at the launch of PISA 2022 Volume III - Creative Minds, Creative Schools on 18 June 2024.
Temple of Asclepius in Thrace. Excavation resultsKrassimira Luka
The temple and the sanctuary around were dedicated to Asklepios Zmidrenus. This name has been known since 1875 when an inscription dedicated to him was discovered in Rome. The inscription is dated in 227 AD and was left by soldiers originating from the city of Philippopolis (modern Plovdiv).
Leveraging Generative AI to Drive Nonprofit InnovationTechSoup
In this webinar, participants learned how to utilize Generative AI to streamline operations and elevate member engagement. Amazon Web Service experts provided a customer specific use cases and dived into low/no-code tools that are quick and easy to deploy through Amazon Web Service (AWS.)
Elevate Your Nonprofit's Online Presence_ A Guide to Effective SEO Strategies...TechSoup
Whether you're new to SEO or looking to refine your existing strategies, this webinar will provide you with actionable insights and practical tips to elevate your nonprofit's online presence.
This presentation was provided by Rebecca Benner, Ph.D., of the American Society of Anesthesiologists, for the second session of NISO's 2024 Training Series "DEIA in the Scholarly Landscape." Session Two: 'Expanding Pathways to Publishing Careers,' was held June 13, 2024.
Submission Ide 88c19114-7d71-4703-b679-22f6c2ee580479 SI.docx
1. Submission Ide: 88c19114-7d71-4703-b679-22f6c2ee5804
79% SIMILARITY SCORE 4 CITATION ITEMS 66
GRAMMAR ISSUES 0 FEEDBACK COMMENT
Internet Source 79%
Institution 0%
Muhammad Aftkhar
Parkinsonism- Pharmaceutical Treatment Plan.docx
Summary
1
Running Header: PARKINSON'S DISEASE
2
PARKINSON'S DISEASE
Parkinson’s disease
Parkinson's disease is a neuro de-generative disease that occurs
and depletes the neurons
present in substansia nigra. These neurons are involved in the
transmission of nerve impulses
-and-
assignment-corection/…
2. -
PARKINSON'S DISEASE
MUHAMMAD AFTKHAR
NUR 635 (GCU)
Mar 4th, 2020
https://www.researchgate.net/profile/Charles_Davie/publication/
5454757_A_review_of_Parkinson's_disease/links/5866522a08ae
8fce490ee2e6/A-review-of-Parkinsons-disease.pdf
https://www.researchgate.net/profile/Charles_Davie/publication/
5454757_A_review_of_Parkinson's_disease/links/5866522a08ae
8fce490ee2e6/A-review-of-Parkinsons-disease.pdf
https://www.sciencedirect.com/science/article/abs/pii/S1474442
218302394
https://www.sciencedirect.com/science/article/abs/pii/S1043661
818321078
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4140171/
from corpus collosum to the susbtansia nigra part of the mid
brain. These are the character
playing neurons in managing voluntary motor movements in the
body. It mostly occurs in elderly
patients describe by involuntary movements and multi-
dimensional brain functioning. The part
of this disease may occur due to the effective and excessive
3. use of medications indulging in bi
polar or Alzheimer's disease (Davie, 2008). The decline of
dopamine in par compacta
deteriorates the normal functioning of the brain in controlling
motor activities.
Prescription medication
The prescribed medications used for Parkinson’s disease
includes the use of Levodopa
directly with replenishes the pool for dopamine
neurotransmitter. This drug can’t be given in a
single dose rather without carbidopa (LODOSYN) the
levodopa will break down into dopamine
and then to epinephrine in the body’s periphery. This will
create severe symptomatic side effects
like an increase in heart rate and sympathetic system
dominancy. Dopa-decarboxylase enzyme
breaks down the levodopa in the periphery so along with
levodopa carbidopa is given. This
inhibits the dopa-decarboxylase enzyme and allows levodopa
to travel into the blood brain
barrier easily.
For the calculations of drug regimen there must be
precautionary measures for kidney
4. and liver sensitive enzyme dependent patients. LFT and RFT’s
for sensitive patients are done to
ensure the correct for dose adjustments not lying in range
affecting kidneys and liver function.
Below are some of the medications for Parkinson’s disease.
3
PARKINSON'S DISEASE
ake: Levodopa
-decarboxylase
6. -dash.: - —
a. Agonist of dopamine: - Use of ergot containing drugs like
bromocriptine, ropinirole
(Requip) and pramipexole (Mirapex). Requip works by
increasing dopamine levels in the
brain. They are used for the patch medication there are some
drugs given in patch
because elder patients sometimes can’t swallow capsules or
tablets may be due to fear so
Neupro is given as a patch that contains rotigotine in it as
active ingredient. Yet another
way to administer medication through injectable which
involves Apokyn has
apomorphine as an active participate of treatment (Xu et.al,
2019).
b. MOA inhibitors: - These are the enzymes that break down the
dopamine in the
periphery of neuron in synaptic cleft. For observing the action
they are blocked by these
MOA inhibitors (mono amine oxidase inhibitors) including
Zelapar, Eldepryl residing
7. selegiline in it.
c. COMT inhibitors: - These are the reuptake channels and
enzymatic control of dopamine
from the synaptic cleft. If they are blocked then there will no
uptake of dopamine in the
neuron and there will be much more dopamine to perform its
function and meet the other
synaptic surface of a leading neuron. Comtan containing
entacapone is used to replenish
dopamine concentration in synaptic cleft and Tasmar as
Tolcapone.
d. Anti-cholinergic: - The use of these mnedications is to
control the frequency of tremors
and muscles movement which results in the deprivation of
energy and loss of nutrients
from cells resulting in weakening of muscle. Cogentin
containing benztropine is the
4
PARKINSON'S DISEASE
5
PARKINSON'S DISEASE
lderly
9. assignment-corection/…
chiefly used drug in regimens prescribed by doctors (
Richardson et.al, 2018) .
e. Non- prescribed drug treatment: - Many ways are there for
those patients who wanted
to mend their way in treating of Parkinson disease. Most
effective practices are exercise,
proper muscle movements and massage therapy, speech and
10. locomotors junction therapy.
Some of the occupational therapy sessions with therapist
recommendations are beneficial
for Parkinsonism. Use of motivated speeches and psychological
sessions will bring
patients from holding the strong grip over their disease and
will think less about it.
Singing could also do a great job in managing the Parkinson
disease symptoms. It will
help the patient to improve on his or her voice which will
result to improved social
interactions. Aqua therapy can also help the patient in terms of
removing the worry or
fear of falling as he or she will be swimming and moving in
water freely. Acupuncture
will reduce the pain and muscle stiffness in the patient’s body (
Giugni & Okun, 2014).
Adverse effects and drug –drug interaction
Most probably the use of drugs for one ailment may cause
damage to other parts of the
body if it left unaware or unattended. Especially in the case of
depression therapy and
medication, some of the drugs are related to the origin of
Parkinson disease. Alzheimer's is a
11. psychotic disorder that may lead to Parkinsonism symptoms
during its treatment. Dementia and
sleeplessness are the most effective adverse effects of drugs
used in Parkinson's disease.
Hallucinations and delusions are also common as these drugs
are used as adjunct therapy for
depression ( Katzenschlager et.al, 2018) .
Warfarin has a severe drug-drug interaction with ropinirole
and this causes an
anticoagulant effect in the blood which forms less solubility of
drug and interaction mode of the
drug in serum plasma is decreased. Medications use for liver
functioning and kidney assistance
like thiazide diuretics and loop diuretic used in hypertensive
patients will get affected by
ropinirole. Gastric drugs for ulcerations and bleeding in the
small intestine may be enhanced by
the use of levodopa. It will bind to complexes formed by
aluminum hydroxide in gastric track
thus inhibits the efficacy of the drug and formulate ulceration.
Pediatrics and geriatrics
Use of a controlled amount of drug regimens in the clinical
setup there must be an
12. important note for breast feeding mothers to restrict the
required dose for Parkinson's disease.
Related to pediatrics calculated initiated amount of dosage
regimen is selected. As ropinirole has
severe dementia effect in children. In children, sudden mood
swings and motor impartment
6
PARKINSON'S DISEASE
during exercise and running is seen. But improved therapy
sessions have presented the group of
medications in one role (Katzenschlager et.al, 2018). Rather put
elder patients in that category
that deals with the slow and shaking movement of facial
muscles and hands, pill rolling
movement and improved muscle rigidity is seen. Geriatrics has
an affective therapeutic goal in
improving dopamine level in the body.
References
13. Davie, C. A. (2008). A review of Parkinson's disease. British
medical bulletin, 86(1), 109-127.
Retrieved from:
https://www.researchgate.net/profile/Charles_Davie/publication/
5454757_A_review_of_Parkins
on's_disease/links/5866522a08ae8fce490ee2e6/A-review-of-
Parkinsons-disease.pdf
Katzenschlager, R., Poewe, W., Rascol, O., Trenkwalder, C.,
Deuschl, G., Chaudhuri, K. R., ...
& Staines, H. (2018). Apomorphine subcutaneous infusion in
patients with Parkinson's disease
with persistent motor fluctuations (TOLEDO): a multicentre,
double-blind, randomised, placebo-
controlled trial. The Lancet Neurology, 17(9), 749-759.
Retrieved from
https://www.sciencedirect.com/science/article/abs/pii/S1474442
218302394
Richardson, K., Fox, C., Maidment, I., Steel, N., Loke, Y. K.,
Arthur, A., ... & Campbell, N. L.
(2018). Anticholinergic drugs and risk of dementia: case-control
study. bmj, 361, k1315.
Xu, W., Reith, M. E., Liu-Chen, L. Y., & Kortagere, S. (2019).
Biased signaling agonist of
14. dopamine D3 receptor induces receptor internalization
independent of β-arrestin recruitment.
Pharmacological research, 143, 48-57. Retrieved from
https://www.sciencedirect.com/science/article/abs/pii/S1043661
818321078
Giugni, J. C., & Okun, M. S. (2014). Treatment of advanced
Parkinson’s disease. Current
opinion in neurology, 27(4), 450. Retrieved from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4140171/
1
Running Header: PARKINSON’S DISEASE
5
PARKINSON’S DISEASE
PARKINSON’S DISEASE
Student’s Name
Tutor’s Name
Course Title
Date
15. Parkinson’s disease refers to a continuous
disarray of the sensory system. This condition is caused by the
genes or environmental factors. There are certain genes that
tend to increase the risk of contracting this condition and some
environmental factors though their chances are small. This
disorder majorly affects motion or movement. It does this by
altering the neurocytes that are found in the black substance.
The neurons are responsible for the transfer of nerve impulses
from the corpus collosum to the middle of the brain particularly
the black substance. These neurocytes are responsible for the
voluntary movement of the body. This disorder is majorly
experienced by elderly people. In most cases it is causes by
excessive usage of medications and the environmental factors
(Ahlskog, 2018). The Parkinson’s disease has the following
signs and symptoms;
· Tremor- A patient suffering from this condition will
experience body shaking, and in most cases, it happens at the
hands. In this case the handshakes while still at rest.
· Slow movements- this condition slows down the patient’s
movements such that doing simple tasks becomes a challenge. It
leads to a lot of time consuming.
· Muscles become rigid- it makes muscles from different parts
of the body become stiff. This causes pain to the patient and
reduces his or her movements.
· Imbalance- One may experience impaired posture and balance.
One finds it very difficult to stand upright and sometimes he or
she may fall.
· Impairment of automatic movements- Actions like blinking,
smiling and swinging of hands by default become a challenge.
One is not able to automatically perform these functions
effectively.
16. · Change of speech-This condition affects and alters the
patient’s nature and way of speaking. The patient may start
speaking slowly, softly or even quickly. The speech may
become a monotone rather that with its normal inflections.
· Changes in writing- A Parkinson’s patient may find it very
difficult to write and in most cases the handwriting becomes
very small. Tremor may also cause the handwriting to be shoddy
and one’s hand will not be stable and still while writing.
Prescription
Parkinson’s disease cannot be cured. Medications
are often used to mitigate the symptoms of this disease.
Sometimes, medical practitioners recommend change of
lifestyle especially bodily exercise. To improve on one’s
speech, it is recommended to seek speech pathologist. The
following medications could be very useful to a patient
suffering from Parkinson’s disease;
· Carbidopa- It is the best medication for this condition. It is an
enzymatic substance which gets into the brain and changes into
Intropin. L-dopa is used together with carbidopa which prevents
L-dopa from being converted into Intropin before reaching the
brain. It also reduces the aftermath of L-dopa such as nausea.
After several years of usage of this drug, it will start to have
less impact on your body. One will also start incurring
involuntary movements if taken in large doses hence the need
for regular control from time to time by the doctor (Mayo
Clinic, 2020).
· Carbidopa-Levodopa infusion- it is given via a tube that
delivers the medication straight into the small intestine in the
form of a gel. This medication is for patients whose disease is
more advanced, though they respond to Carbidopa-Levodopa,
the response is not stable. S small surgery is needed to install
the tube. Having this tube exposes one to infections or
sometimes the tube may fall out (Mayo Clinic, 2020).
· Dopamine agonist-this medication remains the same but it
borrows the brain outcome of dopamine. They are not as strong
as Levodopa but they can be used together with it to smoothen
17. the results of L-dopa. Samples of dopamine agonists are
ropinirole, pramipexole etc. The side effects of this medication
are similar to those of carbidopa-Levodopa but they extend to
hallucinations and sleepiness (Mayo Clinic, 2020).
· MAO B inhibitors- They inhibit the brain enzyme, monoamine
oxidase B, helping in the prevention of breakdown of the brain
dopamine. They include selegiline, Rasagiline and safinamide.
Its side effects include nausea and insomnia. If this medication
is used together with Carbidopa-Levodopa, chances of
hallucinations will increase (Mayo Clinic, 2020).
· COMT inhibitors- This medication lengthens the effect of
Levodopa by standing in the way of an enzyme that that causes
breakdown of dopamine. An example of this inhibitor is the
entacapone. Side effect of these inhibitors includes diarrhea and
involuntary movements. Tolcapone is also a COMT inhibitor
but it is hardly prescribed because of its serious effects on the
liver (Mayo Clinic, 2020).
· Anticholinergics- They has been in use for quite a number of
years and they are used to control Parkinson’s disease tremor.
One example of this medication is benztropine. Its side effects
include confusion, dry mouth, memory loss and constipation
(Mayo Clinic, 2020).
· Amantadine- It offers short time relief. They may be given
together with carbidopa-Levodopa to control the involuntary
movements caused by carbidopa-Levodopa. Its side effects
include hallucinations and ankle swelling (Mayo Clinic, 2020).
Adverse effects and drug-drug interaction
Sometimes, a drug may be used to treat one disease
but end up causing another disease if not carefully taken. It may
be a drug for one disease but when used inappropriately, it may
become a virus or bacteria that will cause a different disease.
When it comes to depression, there are drugs that can treat it
but may end up causing Parkinson’s disease. Treatment of
Alzheimer’s could also lead to Parkinson’s disease symptoms.
Sleepiness and hallucinations are the most common symptoms
of Parkinson’s disease. In drug-drug interaction, warfarin has a
18. severe effect as it causes insolubility of the drug and ends up
reducing the interaction of the drug with the plasma serum
(Katzenschlager et.al, 2018).
Pediatrics and geriatrics
It has been noted that there are many changes that
occur in the life of a child up to puberty. This has led to the
need for pediatric groupings. There are still a lot to discover in
the psychological development and it can only be achieved if
these findings are brought about according to the groups.
Children and adults have different reactions or responses to
treatments. For example, phenobarbitones are very critical and
important in the treatment of cerebral malaria amongst adults.
But the same medication, if administered to children, then it is
likely to cause mortality. The same way corticosteroid can be
used by adults with meningitis, but not with children with the
same condition. There is no adequate guideline that has been
put in place to cater for the analysis of these age groups and the
psychological experiences involved at each group.
Geriatrics is not only for the old as the case may
be inferred by the majority of the people; it could also be very
important and vital for persons who are below the age of sixty.
It is not only geriatricians who can offer geriatrics care; anyone
can connect these seniors to a healthcare that is meant for the
aging minds and bodies. Breast feeding mothers must have a
controlled dosage of Parkinson’s disease medication if at all
they are suffering from the disease. Medications like ropinirole
have adverse effects on children as they may cause mood swings
and malfunctioning of the body parts. Elderly patients should do
slow bodily exercises to improve their body movements.
Geriatrics comes in hand in improving the dopamine levels in
the body of an elderly patient (Katzenschlager et.al, 2018).
19. References
Mayo Clinic. (2020). The Parkinson’s Disease. Retrieved from
https://www.mayoclinic.org/diseases-conditions/parkinsons-
disease/diagnosis-treatment/drc-20376062.
Ahlskog, J. E. (2018, March). Aerobic exercise: evidence for a
direct brain effect to slow
Parkinson disease progression. In Mayo Clinic Proceedings
(Vol. 93, No. 3, pp. 360-372). Elsevier. Retrieved from
https://mail.google.com/mail/u/0/#inbox/FMfcgxwGDWvBxdQg
tkVStCGSBRhgqzMT?projector=1&messagePartId=0.1.
Katzenschlager, R., Poewe, W., Rascol, O., Trenkwalder, C.,
Deuschl, G., Chaudhuri, K. R., ... & Staines, H. (2018).
Apomorphine subcutaneous infusion in patients with
Parkinson's disease with persistent motor fluctuations
(TOLEDO): a multicenter, double-blind, randomized, placebo-
controlled trial. The Lancet Neurology, 17(9), 749-759.
Retrieved from
https://www.sciencedirect.com/science/article/abs/pii/S1474442
218302394.
DQ-1
Eczema is a common, chronic inflammatory skin condition
characterized by dry, itchy skin. Individuals with eczema have a
dysfunctional skin barrier which can be due to genetics where
there is a mutation in the gene filaggrin (Nemeth & Evans,
2019). Filaggrin is an important component for skin cell
maturity and is responsible for making the tough, flat
corneocytes; however, patients with a filaggrin mutation will
20. have an inconsistent organization of the skin cells allowing
water to leak through the skin barrier which will dehydrate the
skin leading to skin irritation (Nemeth & Evans, 2019). Also,
patients with eczema have decreased amounts of bet-defensins
in the skin which are vital peptides that fight off bacteria,
viruses, and fungi. Therefore, patients with eczema are easily
irritated by environmental factors and are more susceptible to
infections.
First-line therapy for eczema includes hydration via over the
counter skin moisturizers that are fragrance-free, ointments,
anti-inflammatory medications, and antihistamines. Topical
corticosteroids can be utilized for acute symptoms and should
only be used a few times a week as long-term use can result in
skin atrophy, striae, acne, and rebound dermatitis (Nemeth &
Evans, 2019). Second-line therapy includes immunomodulators,
such as pimecrolimus and tacrolimus, phototherapy,
immunosuppressants, oral steroids, and alitretinoin.
Pimecrolimus is a topical immunomodulator applied twice daily
on the affected area and can be used as a long-term treatment.
Compared to topical corticosteroids, pimecrolimus is more
beneficial on sensitive and/or think skin and has positive effects
on epidermal integrity (Jovanovic, 2019). However, patients
may experience burning, soreness, stinging, and pruritus for the
first few treatment days (Jovanovic, 2019). Adverse reactions
include skin papilloma, skin infections, acne vulgaris,
hypersensitivity, herpes simplex dermatitis (“Pimecrolimus,”
2019). Additionally, there are theoretical risks that
pimecrolimus may be associated with skin malignancy and
lymphoma, but the FDA agency indicated the safety of its use
including in patients as young as 3 months old and for long-
term management (Jovanovic, 2019). However, black box
warning still indicates that pimecrolimus should not be used in
children <2 years of age. It is also contraindicated in patients
with erythroderma, skin diseases that may potentially increase
systemic absorption such as Netherton’s syndrome, and in
immunocompromised patients (“Pimecrolimus,” 2019). Drug
21. interactions include CYP3A4 inhibitors as it may decrease the
metabolism of pimecrolimus and immunosuppressants which
may enhance adverse effects and toxicity.
References
Jovanovic, M. (2019). Safety of pimecrolimus and tacrolimus in
the topical therapy of atopic dermatitis. Medicinski Pregled, 5–
6, 139-142. doi:10.2298/MPNS1906139J
Nemeth, V., & Evans, J. (2019). Eczema. StatPearls Publishing.
Retrieved from
https://www.ncbi.nlm.nih.gov/books/NBK538209/
Pimecrolimus. (2019). Retrieved from
https://www.drugs.com/ppa/pimecrolimus.html
DQ-2
Psoriasis is a skin disease that is multi factorial in nature and
involves the body’s immune response system (Kalb, 2019).
Psoriasis is unique in the aspect that it has a typical red waxy
scaly skin characteristic (Kalb, 2019). Psoriasis is usually
apaprant at the elbows, knees, scalp, nails, and gluteal cleft
(Kalb, 2019). The diagnosis of psoriasis is based on a skin
biopsy to confirm the diagnosis (Kalb, 2019).
The pathology of psoriasis is characterized by systemic and
local inflammation from deficits and defects in T regulatory
cells and an upregulation of Th-1 and Th-17 cells, antigen-
presenting cells- and cytokines (Kalb, 2019). Treatment focuses
on suppressing interlukin 12, 23, and 17 to stop the
inflammatory process that causes the presentation of psoriasis
(Kalb, 2019). For example a treatment option is
brodalumbwhich is given as a three weekly doses for induction,
followed by every other week thereafter (Kalb, 2019).
Some adverse reactions of brodalumb is injection site reaction,
a 1-2% chance of a cutaneous candida infection, inflammatory
bowel disease exacerbation, depression, and suicidal ideation
(Kalb, 2019). The depression and suicidal ideation could be a
22. combination of self-esteem issues but could be agitated or
exacerbated by brodalumb (Kalb, 2019).
Another interesting fact is that anti-IL-17 and anti-IL-23 classes
have an insert warning that states that there is an infection risk
from long term usage that suppresses the immune system and
that there is an increased cancer risk (Kalb, 2019).
Some interactions of brodalumb include avoiding live vaccines
due to the immunosuppressant nature of brodalumb and also
avoiding grapefruit juice (Siliq, 2017). Brodalumb is also noted
to have a narrow therapeutic index requiring monitoring of the
immune system and dose adjustments as necessary (Siliq, 2017).
References:
Kalb, R. E. (2019). Overcoming Challenges in the Management
of Psoriasis: Treatment Advances to Improve Standard of Care.
Journal of Managed Care Medicine, 22(4), 63–66.
Siliq. (2017). MPR Monthly Prescribing Reference, 8,
3.Retrived from: https://search-ebscohost
.com.lopes.idm.oclc.org/login.aspx?direct=true&db=edsgao&A
N=edsgcl.510111204&site=eds-live&scope=site
DQ-3
Eczema is a chronic skin disorder that affects all ages and often
begins in infancy and can resolve during puberty, but often
returns after that (Woo & Osborn, 2019, pg. 958). The exact
cause is unknown but patients normally have a high IgE
antibody levels and have high correlation with developing
asthma, allergies, or hay fever later on in life. Depending on the
severity of eczema there are over-the-counter medications,
prescription topical medications, phototherapy,
23. immunosuppressants, medications, and other natural treatments
for eczema.
Eczema is usually a rash that develops anywhere on the face,
trunk, scalp, or extremities that causes mild to severe itching.
Patches of skin become inflamed, red, cracked and rough during
times of flare up and can be triggered by a variety of things.
Eczema is an IgE hypersensitivity reaction and involves a
complex immunologic cascade involving defects in the cell-
mediated immune response, IgE dyregulation, and disruption in
the epidermal barrier (Piliang & Schneider, 2019).
Treatment includes hydrating the skin, topical corticosteroids,
antipruitics, emollients, phototherapy, and avoiding triggers.
Patients can take vitamin D, probiotics, use oatmeal baths,
lotions/creams as nonpharmacological treatments. They should
take a 20 minute bath, pat the skin dry and apply emollients
such as eucerin or aquaphor to the skin to lock in the moisture.
Oatmeal baths help with the itching and hydrate the skin as
well. Topical medications can be used such as Protopic
(tacrolimus) that is a macrolide immunosuppressant that is
applied to the skin twice a day. It is not indicated for children
under 2 years old and should be used short term with breaks in
between if needed (Protopic, 2019). It is not a first line therapy
and should be used if the topical steroids fail. Long-term safety
has not been established and the causal relationship has not
been established for skin malignancy but has been reported. It
comes in a 0.03% for pediatric and a 0.1% for adults or kids 16
and over. They need to avoid light therapy, tanning beds, and
sun exposure while using it. There has not been studies with
drug interactions with this but CYP3A4 inhibitors such as
erythromycin, ketoconazole, fluconazole, calcium channel
blockers, and cimetidine should be used with caution.
Piliang, M., & Schneider, S. (2019, July 3). Atopic Dermatitis.
Retrieved February 27, 2020, from
24. http://www.clevelandclinicmeded.com/medicalpubs/diseaseman
agement/dermatology/atopic-dermatitis/default.htm
Protopic - FDA prescribing information, side effects and uses.
(2019, April 1). Retrieved February 27, 2020, from
https://www.drugs.com/pro/protopic.html
Woo, T. M. & Osborn, K. (2019). Dermatological Conditions.
In T. M. Woo & M. V. Robinson (Eds.), Pharmacotherapeutics
for advanced practice nurse prescribers (pp. 957-989).
Philadelphia, PA: F. A. Davis Company.
Need help to reply three post.
DO NOT JUST REPEAT SAME INFORMATION, DO NOT
JUST SAY I AGREE OR THINGS LIKE THAT. YOU NEED
TO ADD NEW INFORMATION TO DISCUSSION.
1- Each reply should be at least 200 words.
2- One scholarly reference ( NO MAYO CLINIC/ AHA)
3- APA style needs to be followed.
4- Each response should have reference at the end
5- Reference should be within last 5 years